- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04488094
Diagnostic Validity of [18F]FSPG PET for the Assessment of Acute Rejection After Heart or Liver Transplantation
A Phase 2, Open-label, Non-randomized, Single Center Study to Explore Diagnostic Performance of [18F]FSPG PET/CT for the Assessment of Acute Allograft Rejection After Heart or Liver Transplantation
Study Overview
Status
Intervention / Treatment
Detailed Description
This open label, non-randomized, single center, single-dose exploratory study is designed to obtain imaging assessments using PET/CT with [18F]FSPG in patients with heart transplantation (HT, n = 10) and liver transplantation (LT, n = 10). Subjects who underwent or scheduled to undergo biopsy for histologic diagnosis of acute rejection will be enrolled.
The study comprises 3 periods: screening, treatment, and follow-up. The screening period starts with the subject's signature on the informed consent form and ends with assignment to treatment that is inclusion of the subject for treatment. The treatment period starts with baseline measurements, and ends with the last measurement/procedure on the day following injection of 200 MBq of [18F]FSPG. The follow-up period contains the end-of-study interview. Key measurement is the PET/CT image acquisition about one hour after the single injection of [18F]FSPG. For evaluation of safety, adverse events (AE) will be monitored and recorded during the study period.
This study will be monitored regularly by a clinical research associate from the sponsor or a designated contract research organization. Data quality and study integrity will be assessed. The investigator will document the items that are required to evaluate the study in the subject files. Data required according to this protocol are to be recorded on the case report forms provided by the sponsor as soon as possible.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Jae Eun Kim, PM
- Phone Number: +82-2-3010-4572
- Email: kje0216@amc.seoul.kr
Study Locations
-
-
-
Seoul, Korea, Republic of, 05505
- Asan Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subject is aged between 19 and 79 years and male or female of any race/ethnicity.
- Subject received heart transplantation or liver transplantation at least 30 days prior to screening
- Subject underwent or is scheduled to undergo biopsy for histologic diagnosis of acute rejection within 7 days prior to or after the planned [18F]FSPG PET/CT administration.
Exclusion Criteria:
- Subject or subject's legally acceptable representative does not provide written informed consent.
- Dose escalation of the current immunosuppressant drugs or starting a new immunosuppressant is scheduled from the study enrollment to the scheduled day of biopsy, or 24 hours after [18F]FSPG administration
- Female subject is pregnant or nursing. Exclusion of the possibility of pregnancy is made by one of the following: 1) Woman is physiologically post-menopausal (cessation of menses for more than 2 years), 2) woman is surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy, or 3) if the woman is of childbearing potential, a serum or urine pregnancy test performed within 24 hours immediately prior to administration of [18F]FSPG has to be negative and the women is advised to apply contraceptive measures during her participation in this study.
- Subject has concurrent severe and/or uncontrolled and/or unstable medical disease (e.g. congestive heart failure, acute myocardial infarction, severe pulmonary disease, chronic renal or hepatic disease which could compromise participation in the study) in the judgment of the investigator.
- Subject is a relative of the investigator, student of the investigator or otherwise dependent.
- Subject has received any investigational drugs or devices within four weeks prior to the study enrollment or within 24 hours after administration of [18F]FSPG.
- Subject has been previously included in this study.
- Subject has any other condition or personal circumstances that, in the judgment of the investigator, might make collection of complete data difficult or impossible.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Heart transplantation
Patients suspected of having acute heart allograft rejection after heart transplantation will receive a single IV injection of [18F]FSPG
|
A radioactive dose of 200 MBq of the study drug with a total quantity of ≤ 100 µg will be administered as slow intravenous bolus injection over up to 60 seconds.
PET/CT examinations will be performed at 60-75 min after the administration of [18F]FSPG.
Other Names:
|
Experimental: Liver transplantation
Patients suspected of having acute liver allograft rejection after heart transplantation will receive a single IV injection of [18F]FSPG
|
A radioactive dose of 200 MBq of the study drug with a total quantity of ≤ 100 µg will be administered as slow intravenous bolus injection over up to 60 seconds.
PET/CT examinations will be performed at 60-75 min after the administration of [18F]FSPG.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sensitivity and specificity of qualitative [18F]FSPG PET/CT interpretation for the diagnosis of patients with histologic evidence of acute allograft rejection
Time Frame: within 7 days of [18F]FSPG PET/CT
|
sensitivity = (the number of [18F]FSPG PET/CT-positive patients divided by the number of rejection positive patients on the histological evaluation) x 100; specificity = (the number of [18F]FSPG PET/CT-negative patients divided by the number of rejection negative patients on the histological evaluation) x 100
|
within 7 days of [18F]FSPG PET/CT
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Association between quantitative [18F]FSPG uptake and histologic grade of rejection
Time Frame: within 7 days of [18F]FSPG PET/CT
|
The association between [18F]FSPG uptake and the histologic grades of rejection activity using Pearson or Spearman rank correlation coefficient
|
within 7 days of [18F]FSPG PET/CT
|
Inter-reader variability
Time Frame: within 1 day of [18F]FSPG PET/CT
|
Inter-reader variability of [18F]FSPG uptake score measured using the kappa statistic
|
within 1 day of [18F]FSPG PET/CT
|
Incidence of treatment emergent adverse events
Time Frame: From the administration of [18F]FSPG to one day after [18F]FSPG PET/CT
|
Number of participants with treatment emergent adverse events graded by the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0)
|
From the administration of [18F]FSPG to one day after [18F]FSPG PET/CT
|
Blood pressure
Time Frame: Pre-treatment and three hours after the administration of [18F]FSPG
|
mmHg
|
Pre-treatment and three hours after the administration of [18F]FSPG
|
Heart rate
Time Frame: Pre-treatment and three hours after the administration of [18F]FSPG
|
beats/minute
|
Pre-treatment and three hours after the administration of [18F]FSPG
|
Body temperature
Time Frame: Pre-treatment and three hours after the administration of [18F]FSPG
|
Celsius
|
Pre-treatment and three hours after the administration of [18F]FSPG
|
Physical examination
Time Frame: Pre-treatment and three hours after the administration of [18F]FSPG
|
The limited physical examination will comprise: general appearance, skin, neck, lungs, heart, abdomen, and a limited neurological examination (mental status, motor strength and sensor perception)
|
Pre-treatment and three hours after the administration of [18F]FSPG
|
Blood tests for safety
Time Frame: Pre-treatment and three hours after the administration of [18F]FSPG
|
The clinical laboratory safety parameters to be assessed are as follows: glutamate pyruvate transaminase (GPT/ALAT), glutamate-oxaloacetate transaminase (GOT/ASAT), alkaline phosphatase, total bilirubin, creatinine, potassium, sodium, total protein, blood urea nitrogen (BUN), albumin
|
Pre-treatment and three hours after the administration of [18F]FSPG
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Dae Hyuk Moon, MD, Asan Medical Center
Publications and helpful links
General Publications
- Baek S, Mueller A, Lim YS, Lee HC, Lee YJ, Gong G, Kim JS, Ryu JS, Oh SJ, Lee SJ, Bacher-Stier C, Fels L, Koglin N, Schatz CA, Dinkelborg LM, Moon DH. (4S)-4-(3-18F-fluoropropyl)-L-glutamate for imaging of xC transporter activity in hepatocellular carcinoma using PET: preclinical and exploratory clinical studies. J Nucl Med. 2013 Jan;54(1):117-23. doi: 10.2967/jnumed.112.108704. Epub 2012 Dec 11.
- Baek S, Choi CM, Ahn SH, Lee JW, Gong G, Ryu JS, Oh SJ, Bacher-Stier C, Fels L, Koglin N, Hultsch C, Schatz CA, Dinkelborg LM, Mittra ES, Gambhir SS, Moon DH. Exploratory clinical trial of (4S)-4-(3-[18F]fluoropropyl)-L-glutamate for imaging xC- transporter using positron emission tomography in patients with non-small cell lung or breast cancer. Clin Cancer Res. 2012 Oct 1;18(19):5427-37. doi: 10.1158/1078-0432.CCR-12-0214. Epub 2012 Aug 14.
- Koglin N, Mueller A, Berndt M, Schmitt-Willich H, Toschi L, Stephens AW, Gekeler V, Friebe M, Dinkelborg LM. Specific PET imaging of xC- transporter activity using a (1)(8)F-labeled glutamate derivative reveals a dominant pathway in tumor metabolism. Clin Cancer Res. 2011 Sep 15;17(18):6000-11. doi: 10.1158/1078-0432.CCR-11-0687. Epub 2011 Jul 12.
- Chae SY, Choi CM, Shim TS, Park Y, Park CS, Lee HS, Lee SJ, Oh SJ, Kim SY, Baek S, Koglin N, Stephens AW, Dinkelborg LM, Moon DH. Exploratory Clinical Investigation of (4S)-4-(3-18F-Fluoropropyl)-L-Glutamate PET of Inflammatory and Infectious Lesions. J Nucl Med. 2016 Jan;57(1):67-9. doi: 10.2967/jnumed.115.164020. Epub 2015 Oct 15.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- FSPG-1902
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Transplantation
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationCzechia, France, Italy, Poland, United Kingdom
-
The Hospital for Sick ChildrenCompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationCanada
-
Astellas Pharma Europe Ltd.TerminatedLiver Transplantation | Kidney Transplantation | Heart TransplantationBelgium, France, Germany, Poland, Spain, United Kingdom
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationSpain, Australia, France, Germany, Canada, Italy, United Kingdom, Belgium, South Africa, Switzerland, Sweden, United States, Austria, Brazil, Czechia, Denmark, Finland, Hungary, Ireland, Mexico, Netherlands, New Zealand, Poland
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationBelgium, France, Germany, Poland, Spain, United Kingdom
-
Astellas Pharma Europe Ltd.Active, not recruitingLiver Transplantation | Kidney Transplantation | Heart Transplantation | Lung Transplantation | Intestine TransplantationBelgium, Czechia, France, Germany, Italy, Poland, United Kingdom
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingLiver Transplantation | Kidney TransplantationFrance
-
Astellas Pharma China, Inc.CompletedLiver Transplantation | Kidney TransplantationChina
-
Astellas Pharma China, Inc.CompletedLiver Transplantation | Kidney TransplantationChina
-
Rennes University HospitalCompletedLiver Transplantation | Kidney TransplantationFrance
Clinical Trials on [18F]FSPG
-
Asan FoundationCompletedInflammatory Bowel Diseases | Crohn Disease | Ulcerative ColitisKorea, Republic of
-
Stanford UniversityGE HealthcareTerminatedMyocardial Inflammation | Cardiac SarcoidosisUnited States
-
Guy's and St Thomas' NHS Foundation TrustKing's College LondonNot yet recruitingCancer | Diagnosis | Resistant Cancer | Response, Acute Phase
-
Life Molecular Imaging SATerminated
-
M.D. Anderson Cancer CenterActive, not recruitingHead and Neck Cancer | Head and Neck Squamous Cell CarcinomaUnited States
-
Andrei IagaruNational Cancer Institute (NCI)CompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Metastatic Renal Cell Cancer | Stage III Renal Cell Cancer | Stage IV Non-Small Cell Lung Cancer | Stage IV Breast Cancer | B-Cell Neoplasm | Stage IIIA Breast Cancer | Stage IV Renal Cell Cancer | Stage IIIC Breast Cancer | Estrogen... and other conditionsUnited States
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)WithdrawnStage IIIA Fallopian Tube Cancer | Stage IIIA Ovarian Cancer | Stage IIIA Primary Peritoneal Cancer | Stage IIIB Fallopian Tube Cancer | Stage IIIB Ovarian Cancer | Stage IIIB Primary Peritoneal Cancer | Stage IIIC Fallopian Tube Cancer | Stage IIIC Ovarian Cancer | Stage IIIC Primary Peritoneal Cancer and other conditions
-
Genentech, Inc.Completed
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingCholangiocarcinoma | Adult Hepatocellular Carcinoma | Resectable Hepatocellular Carcinoma | Benign Liver Tumor | Metastases to LiverUnited States
-
Adam BrickmanNational Institute on Aging (NIA)Completed